170 related articles for article (PubMed ID: 20207816)
1. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.
Ye Y; Keyes KT; Zhang C; Perez-Polo JR; Lin Y; Birnbaum Y
Am J Physiol Heart Circ Physiol; 2010 May; 298(5):H1454-65. PubMed ID: 20207816
[TBL] [Abstract][Full Text] [Related]
2. Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions.
Ye Y; Lin Y; Atar S; Huang MH; Perez-Polo JR; Uretsky BF; Birnbaum Y
Am J Physiol Heart Circ Physiol; 2006 Sep; 291(3):H1158-69. PubMed ID: 16603698
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner.
Hausenloy DJ; Whittington HJ; Wynne AM; Begum SS; Theodorou L; Riksen N; Mocanu MM; Yellon DM
Cardiovasc Diabetol; 2013 Oct; 12():154. PubMed ID: 24148218
[TBL] [Abstract][Full Text] [Related]
4. Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice.
Ye Y; Lin Y; Manickavasagam S; Perez-Polo JR; Tieu BC; Birnbaum Y
Am J Physiol Heart Circ Physiol; 2008 Dec; 295(6):H2436-46. PubMed ID: 18931027
[TBL] [Abstract][Full Text] [Related]
5. Oral glyburide, but not glimepiride, blocks the infarct-size limiting effects of pioglitazone.
Ye Y; Lin Y; Perez-Polo JR; Birnbaum Y
Cardiovasc Drugs Ther; 2008 Dec; 22(6):429-36. PubMed ID: 18825491
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes.
Ye Y; Qian J; Castillo AC; Ling S; Ye H; Perez-Polo JR; Bajaj M; Birnbaum Y
Am J Physiol Heart Circ Physiol; 2013 Jan; 304(1):H131-41. PubMed ID: 23103492
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase-4 inhibition attenuates arrhythmias via a protein kinase A-dependent pathway in infarcted hearts.
Lee TM; Chen WT; Chang NC
Circ J; 2015; 79(11):2461-70. PubMed ID: 26399925
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism.
Liu L; Liu J; Wong WT; Tian XY; Lau CW; Wang YX; Xu G; Pu Y; Zhu Z; Xu A; Lam KS; Chen ZY; Ng CF; Yao X; Huang Y
Hypertension; 2012 Sep; 60(3):833-41. PubMed ID: 22868389
[TBL] [Abstract][Full Text] [Related]
9. Additive effect of TAK-491, a new angiotensin receptor blocker, and pioglitazone, in reducing myocardial infarct size.
Ye Y; Keyes KT; Zhang CF; Perez-Polo JR; Lin Y; Birnbaum Y
Cardiovasc Drugs Ther; 2010 Apr; 24(2):107-20. PubMed ID: 20379769
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl Peptidase 4 Inhibition Alleviates Shortage of Circulating Glucagon-Like Peptide-1 in Heart Failure and Mitigates Myocardial Remodeling and Apoptosis via the Exchange Protein Directly Activated by Cyclic AMP 1/Ras-Related Protein 1 Axis.
Aoyama M; Kawase H; Bando YK; Monji A; Murohara T
Circ Heart Fail; 2016 Jan; 9(1):e002081. PubMed ID: 26721911
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR-γ-independent manner.
Birnbaum Y; Long B; Qian J; Perez-Polo JR; Ye Y
Basic Res Cardiol; 2011 May; 106(3):431-46. PubMed ID: 21360043
[TBL] [Abstract][Full Text] [Related]
12. Novel Potentials of the DPP-4 Inhibitor Sitagliptin against Ischemia-Reperfusion (I/R) Injury in Rat Ex-Vivo Heart Model.
Al-Awar A; Almási N; Szabó R; Takacs I; Murlasits Z; Szűcs G; Török S; Pósa A; Varga C; Kupai K
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30340421
[TBL] [Abstract][Full Text] [Related]
13. Aspirin augments 15-epi-lipoxin A4 production by lipopolysaccharide, but blocks the pioglitazone and atorvastatin induction of 15-epi-lipoxin A4 in the rat heart.
Birnbaum Y; Ye Y; Lin Y; Freeberg SY; Huang MH; Perez-Polo JR; Uretsky BF
Prostaglandins Other Lipid Mediat; 2007 Feb; 83(1-2):89-98. PubMed ID: 17259075
[TBL] [Abstract][Full Text] [Related]
14. New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin.
Gagliardino JJ; Santoro S; Arellano S; Di Girolamo G
Expert Opin Pharmacother; 2008 Jun; 9(9):1495-507. PubMed ID: 18518780
[TBL] [Abstract][Full Text] [Related]
15. Protective effects of sitagliptin on myocardial injury and cardiac function in an ischemia/reperfusion rat model.
Chang G; Zhang P; Ye L; Lu K; Wang Y; Duan Q; Zheng A; Qin S; Zhang D
Eur J Pharmacol; 2013 Oct; 718(1-3):105-13. PubMed ID: 24041927
[TBL] [Abstract][Full Text] [Related]
16. Sitagliptin attenuates intestinal ischemia/reperfusion injury via cAMP/PKA, PI3K/Akt pathway in a glucagon-like peptide 1 receptor-dependent manner.
Khedr RM; Ahmed AAE; Kamel R; Raafat EM
Life Sci; 2018 Oct; 211():31-39. PubMed ID: 30195035
[TBL] [Abstract][Full Text] [Related]
17. Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue.
Sangle GV; Lauffer LM; Grieco A; Trivedi S; Iakoubov R; Brubaker PL
Endocrinology; 2012 Feb; 153(2):564-73. PubMed ID: 22186413
[TBL] [Abstract][Full Text] [Related]
18. An interaction between glucagon-like peptide-1 and adenosine contributes to cardioprotection of a dipeptidyl peptidase 4 inhibitor from myocardial ischemia-reperfusion injury.
Ihara M; Asanuma H; Yamazaki S; Kato H; Asano Y; Shinozaki Y; Mori H; Minamino T; Asakura M; Sugimachi M; Mochizuki N; Kitakaze M
Am J Physiol Heart Circ Physiol; 2015 May; 308(10):H1287-97. PubMed ID: 25747753
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A.
Oeseburg H; de Boer RA; Buikema H; van der Harst P; van Gilst WH; Silljé HH
Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1407-14. PubMed ID: 20448207
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical, apoptotic and biochemical changes by dipeptidyl peptidase-4 inhibitor-sitagliptin in type-2 diabetic rats.
Karabulut S; Coskun ZM; Bolkent S
Pharmacol Rep; 2015 Oct; 67(5):846-53. PubMed ID: 26398375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
